Roxithromycin
Roxithromycin has been studied in 4 papers since 2018: none in people yet, 1 in animals, 1 in cells, 1 review; 1 in the past year. The research so far is in animals and cells. The newest paper, Jan 15, 2026: “Comparative efficacy of pharmacological agents on abdominal aortic aneurysm growth rate: a systematic review and network meta-analysis”.
See all 4 papers on roxithromycin
At a glance
The findings reach people, from one lab or study. 2 independent labs in 1 country; 1 trial, none about aging, 1 with no results posted.
None of its findings points the other way.
- 2 independent labs in 1 country
- 1 trial, none about aging, 1 with no results posted
- Funders: K. C. Wong Education Foundation and 4 more
- Animals1
- Cells1
- In silico1
What did studies of roxithromycin find?
4Studies of roxithromycin measured 4 outcomes, among them abdominal aortic aneurysm growth rate, NOX4 and cellular senescence.
Abdominal aortic aneurysm growth rate
downin humans1
1 study
Abdominal aortic aneurysm growth rate
downin humans1
Roxithromycin decreases abdominal aortic aneurysm growth rate in humans (Pooled randomized controlled trials) (SMD 0.39, 95% CrI -0.69 to -0.10 (as reported)).
“Pooled RCT results showed roxithromycin significantly reduced AAA growth (SMD [95% CrI]: 0.39 [-0.69 to -0.10]).”
ReviewPooled randomized controlled trialsabdominal aortan = 2,135
Frontiers in pharmacology
NOX4
downin mouse cells1
1 study
NOX4
downin mouse cells1
Roxithromycin inhibits NOX4 in mouse cells.
“NADPH oxidase 4 (NOX4), implicated in lung fibrosis and cell senescence, was shown to be inhibited by RXM treatments.”
Cells
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Acta pharmacologica Sinica
Cellular senescence
downin mice1
1 study
Cellular senescence
downin mice1
Roxithromycin decreases cellular senescence in mice (bleomycin-induced model).
“the senescent phenotype of lung tissues induced by BLM was significantly diminished after RXM administration”
Animalsbleomycin-induced modellung
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Acta pharmacologica Sinica
Pulmonary fibrosis
downin mice1
1 study
Pulmonary fibrosis
downin mice1
Roxithromycin decreases pulmonary fibrosis in mice (bleomycin-induced pulmonary fibrosis model).
“RXM was shown to attenuate lung injury, inflammation, and fibrosis.”
Animalsbleomycin-induced pulmonary fibrosis modellung
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Acta pharmacologica Sinica
Trial sponsors
The Affiliated Hospital Of Guizhou Medical University
1 trialPhase 139 people